marti-test demonstrates that anti-mycolic acid antibodies
TRANSCRIPT
![Page 1: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/1.jpg)
MARTI-test demonstrates that anti-mycolic acid antibodies are surrogate markers for active TB
Jan Verschoor
1
Department of Biochemistry
![Page 2: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/2.jpg)
TuberculosisA cough or sneeze from a person with active TB can leave droplets that contain mycobacteria in the air for 5 hours.
Inhalation of those dropletsmay cause TB, especially in the HIV compromised challenged person.
2
![Page 3: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/3.jpg)
Prognosis of TBCurable disease, requiring nine months of combination therapyCompromised by:
Co-infection with HIV Reduces life expectancy to weeks if left untreatedComplicates diagnosis:
Standard methods underestimate by 30% M avium disease
Drug resistanceConsumes most of the budget to control TB in SA
3
![Page 4: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/4.jpg)
WHO report: Global TB control 2009
4
![Page 5: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/5.jpg)
TB diagnosis: State of the artExposure: Skin test – once only
replaced with Interferon-γ release assays (IGRA) –frequent repeats possible to monitor clinical staff at risk.
Active disease: Sputum culture (6 wks) replaced with
Nucleic Acid Amplification Tests (NAAT) – sputum based (3 days)
5
![Page 6: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/6.jpg)
TB diagnosis: TB disease challengesPaediatric TB
Hyper-susceptibility in the 1 – 5 year olds: no sputum samples, often extrapulmonaryHigh natural resistance to TB in 5-12 year olds
HIV patientsSkin test and chest x-ray fail due to immune anergyExtrapulmonary TB manifestationDisease due to non-TB mycobacteria
Nosocomial TB in TB/HIV burdened environment
6
![Page 7: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/7.jpg)
New diagnostics: targets (1)…
7
Mycobacterial components: Proteins, lipids and nucleic acids – FIND focus on nucleic acids
www.finddiagnostics.org
![Page 8: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/8.jpg)
New diagnostics: targets (2)…
8
Mycobacterial components: FIND secondary focus on lipids: LAM
www.finddiagnostics.org
![Page 9: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/9.jpg)
New diagnostics: targets (3)…
9
Surrogate markers for TBAntibodies … but to which antigen?
www.finddiagnostics.org
![Page 10: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/10.jpg)
Requirements for TB disease serodiagnostics
Antibody activity to remain unaffected by HIV
Blind towards previous vaccinations and skin tests -should have short memory
Blind towards Non-TB mycobacteria infection
Sensitive, specific and reproducible
Affordable, amenable to field screening, easy to automate and operate
10
![Page 11: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/11.jpg)
The opportunity provided by mycolic acids from the Mtb cell wall
1. outer lipids 2. mycolic acid 3. polysaccharides
(arabinogalactan) 4. peptideglycan5. plasma membrane 6. lipoarabinomannan (LAM) 7. phosphatidylinositol
mannoside8. cell wall skeleton
11
Schematic diagram of Mycobacterial cell wall.
![Page 12: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/12.jpg)
Mycolic acids: Unique cell wall wax
Most abundant cell wall lipid
Pumped out as biofilm matrix*
Distributed in the body by lipoproteins
12*Ohja et al. (2008) Mol. Microbiol. 69: 164
![Page 13: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/13.jpg)
Mycolic acids (MA) = Mtb identikitUnique MA composition each for 60 different species of Mycobacterium!Mycobacterial MA molecules larger than from other species, eg Nocardia and CorynebacteriumThree main classes of MA for M. tuberculosis:
13
![Page 14: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/14.jpg)
Mycolic acids and immunity: 1994Breakthrough, Harvard, USA: A lipid (MA) presenting role described for the CD1 protein on antigen presenting cells:
Stimulation of T cell immunity (and antibodies?) without needing the CD4 T helper cell1. A possibility to bolster immunity in HIV infected patients with MA2.Diagnosis: Anti-MA antibodies as surrogate markers?
14
1. Beckman et al. (1994) Nature 372: 6912. Verschoor & Onyebujoh (1999) Bioessays 21: 365-366
![Page 15: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/15.jpg)
Mycolic acids antibody assays
Serodiagnosis to detect anti-TB antibodies is impaired by HIV-infection1
Antibodies to MA not affected by HIV/AIDS2
Popular antibody tests not to desired standardBiosensor technology can overcome thisBiosensor technology is laboratory bound, complexBiosensors are being automated and simplified, similar to what is currently being achieved with NAAT
151. Clin. Inf. Dis. (2004) 39: e1-e7 , 2. Clin. Chem. Lab. Med. (2002) 40: 882
![Page 16: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/16.jpg)
Anti-MA antibodies in HIV patients
Schleicher et al. (2002) Clin. Chem. Lab. Med. (2002) 40: 88216
![Page 17: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/17.jpg)
Introducing the MARTI-test
M - Mycolic acid
A - Antibody
RT - Real-time
I - inhibition
17
X YOH
OOH
X
abc
Anti-MA antibodies
![Page 18: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/18.jpg)
1818
How MARTI Works
![Page 19: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/19.jpg)
Short memory of antibodies: 21 blind samples (EDCTP – Univ Stellenbosch)
-40-30-20-10
0102030405060708090
0 10 20 30 40 50 60 70 80 90 100
Days into treatment
MA
RTI
-sig
nal (
%)
.
19
![Page 20: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/20.jpg)
20
MARTI in MDR patient (EDCTP P5121)
-
10
20
30
40
50
60
70
80
Week 0 Week 1 Week 2 Week 4 Week 6 Months6
Months12
Period
Sig
nal %
inhi
bitio
n
![Page 21: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/21.jpg)
21
MARTI in cured TB patient (EDCTP P3897)
-50
-40
-30
-20
-10
-
10
20
30
40
50
Week 0 Week 2 Week 4 Week 6 Months 6 Months 12
Period
Sign
al %
inhi
bitio
n
False negative: Can be excluded by spiking with monoclonal antibody?
![Page 22: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/22.jpg)
MARTI-test niche – overall costs
Current available diagnostics: TotalR18 980 R59 010 R77 990
R56 500MARTI-tests for all suspects
Downstream savings (clinic fees, hospitalization, decreased transmissions R100,000s
Gauteng: proposed flowchart for PCR diagnosis, Dr GerritCoetzee, Head of the NHLS National TB Reference Laboratory
![Page 23: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/23.jpg)
MARTI-test nowA South African inventionPCT patent (2005), granted in 2008, tested at >80% accuracy
False negatives avoided: >90% accuracy
Proof of principle in wave-guide biosensor: Thanyani et al. (2008) J Immunol Methods 332: 61-72
Methodology in SPR biosensor (EDCTP)Lemmer et al. (2009) Methods in Enzymology (In press)
Methodology in electro-impedance (EDCTP) Mathebula et al. (2009) Chem Comm 2009:3345-3347
23
![Page 24: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/24.jpg)
MARTI-test futureCape Biotech: Validation in HIV / avoidance of M avium disease
India - South Africa bilateral agreementMARTI application in child TB and extrapulmonary TB
MRC:Three year validation for sensitivity and specificity
To be coordinated and applied for:Biosensor hardware engineering for high sample throughput
24
![Page 25: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/25.jpg)
Acknowledgements: international
Jan Castrop Eco Chemie NLBiosensor hardware development
Mark Baird Bangor University UKChemical synthesis of mycolic acids
EDCTP EUFunding to initiate translational research
25
![Page 26: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/26.jpg)
Acknowledgements: national
P van Helden and team Univ. Stellenbosch
Hulda Swai and team CSIR
NRF, MRC, Cape Biotech/Lifelab
26
![Page 27: MARTI-test demonstrates that anti-mycolic acid antibodies](https://reader034.vdocument.in/reader034/viewer/2022052108/62883c9d2d437243c96b1c26/html5/thumbnails/27.jpg)
Acknowledgements: TB Team
+ Anton Stoltz, Cathryn Driver, Yvonne Maas, Monica Gomes,Hannelie Korf, Mohammed Balogun, Pieter Vrey, Gilbert Siko
27